Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 27;10(2):82–90. doi: 10.36469/001c.87853

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Figure 3. — The top 5 1L regimens included cisplatin; however, as the median OS for cisplatin (N=65) was not reported, only the top 4 regimens are included in panel A.

Panel A: IQR for carboplatin plus paclitaxel, 9.5-67.7 months; IQR for cisplatin, 28.1 months -NR; IQR for megestrol, 13.4 months -NR; IQR for bevacizumab plus carboplatin plus paclitaxel, 12.3-66.6 months; IQR for carboplatin plus docetaxel, 6.4-50.6 months.

Panel B: IQR for LOT1, 9.2-73.0 months; IQR for LOT2, 6.4-46.6 months; IQR for LOT3, 5.4-35.5 months.

Abbreviations: 1L, first-line; IQR, interquartile range; LOT, line of therapy; NR, not reported; OS, overall survival.